Abstract
independent prognostic factor for OS in patients with locoregional recurrence (P=0.042), whereas EBV DNA independently predicted OS for the patients with distant recurrence (P=0.007). For those patients with undetectable EBV DNA, SUV max <8.65 was still an independent favorable prognostic factor (P=0.038).
Introduction
Nasopharyngeal carcinoma (NPC) is common in southern China, especially in the Guangdong province, where rates range from 20 to 30 cases per 100,000 population. [1, 2] Radiotherapy is the primary treatment modality for NPC, and concurrent chemo-radiotherapy (CCRT) with or without adjuvant chemotherapy is the standard treatment regimen for locoregional advanced disease. [3, 4] Despite significant improvements in local control due to advances in radiotherapy and combined modality treatments, local recurrence and distant metastasis remain the predominant mode of failure in patients with advanced NPC. [5, 6] Locoregional recurrent NPC re-irradiated by IMRT can still have an encouraging outcome; the 5-year local control rate (LCR) and overall survival rate (OS) for recurrent stage I, II, III and IV were 80.0%, 85.0%, 80.0% and 78.7% and 71.4%, 62.9%, 35 .5% and 30.2%, respectively. [7] However, when distant metastases are present, the median survival for metastatic NPC is only 12-20 months. [8] There remains a mysterious heterogeneity of outcomes for patients with locoregional or distant recurrence. Therefore, the identification of effective prognostic factors that more accurately correlate with treatment outcome would be of great importance for determining which NPC patients might benefit from intense treatment. [9] Currently, the most important and widely recognized prognostic factor identified to date is the AJCC tumor-node metastasis (TNM) staging system. [10] [11] [12] However, previous studies demonstrated that the clinical TNM staging for patients with recurrence and distant metastasis does not always provide a satisfactory prediction. [13] Accordingly, an increasing amount of effort is being devoted to identifying better prognostic markers to supplement the staging system. Epstein-Barr virus DNA is a marker that has long been intensively studied and is considered a useful tool to supplement the TNM system for prognostication in NPC. [14] The prognostication value of EBV DNA in recurrent NPC has been demonstrated in several studies. [15] [16] [17] However, in some cases of recurrent NPC, patients presented with undetectable levels of EBV DNA. [18] In addition, although EBV DNA levels were detectable, the amount of data on the EBV DNA load of patients with locoregional recurrent NPC is relatively low. [17] Recent studies have addressed the role of 18 F-fluoro-2-deoxy-D-glucose positron emission tomography ( 18 F-FDG-PET) maximal standard uptake value (SUV max ) as a risk stratification marker to predict therapeutic response or outcome in patients with head and neck cancers, [19, 20] lung cancer, [13] and NPC. [9] , [21] , [22] Notably, studies on the prognostic value of SUV max are mostly focused on the pretreatment SUV max of patients; however, data to evaluate the prognostic role of SUV max for patients with locoregional recurrence or distant recurrence are rare. Furthermore, the comparison of the role of EBV DNA load and SUV max in predicting the outcome of patients with recurrent NPC has not yet been well defined. Therefore, in the present study, we aimed to determine and compare the prediction value of 18 F-FDG PET/CT scan SUV max and EBV DNA load in locoregional or distant recurrent NPC patients.
Materials and Methods Patients
We retrospectively analyzed initial recurrent NPC patients who were referred to Sun Yat-sen University Cancer Center, Guangzhou, China between July 2007 and December 2013. All patients had received radiotherapy alone, concurrent chemo-radiotherapy (CCRT) or induction chemotherapy followed by CCRT, depending on the stage of disease on initial presentation. When patients clinically indicated with locoregional recurrence or distant recurrence, wholebody 18 F-FDG PET examination and EBV DNA measurement were performed on each patient before salvage treatment. In addition to 18 F-FDG PET, magnetic resonance imaging (MRI) of the head and neck and conventional workups, including physical examinations, endoscopy, chest radiography, whole-body bone scans, and abdominal ultrasonography, were performed depending on the status of each patient. These examinations were performed within 2 weeks of enrollment in the study. All enrolled patients received salvage treatment using platinum-based adjuvant chemotherapy. Patients were excluded who met the following criteria: (1) PET/CT imaging PET/CT imaging was performed with a combination PET/CT scanner (Discovery ST 16; GE Healthcare, Little Chalfont, United Kingdom) according to published guidelines for tumor imaging with PET/CT. [24] Helical CT was performed from the head to the proximal thigh before PET acquisition according to a standardized protocol. PET/CT scans from the head to the proximal thigh were begun 45 to 60 minutes after the injection of 5.55 MBq/kg of FDG. The PET images were reconstructed with the use of CT data for attenuation correction with an ordered-subset expectation maximization iterative reconstruction algorithm. The standardized FDG uptake value was calculated using the concentration of FDG in the region of interest, as measured by PET, divided by the injected FDG dose and multiplied by body weight as a normalization factor. The SUV max for each patient was used to minimize partial-volume effects.
The SUV max values of locoregional and distant metastases were used as SUV max for the locoregional recurrent group and the distant recurrent group, respectively.
Plasma EBV DNA measurement
As previously described, [15, 25, 26] patient plasma EBV DNA (EBV DNA) concentrations were routinely measured by q-PCR before salvage treatment.
Statistical analysis
The Statistical Package for the Social Sciences software (SPSS v. 17, SPSS, Inc., Chicago, IL) was used for data analysis. The receiver operating characteristic (ROC) curve determined the optimal cutoff value for EBV-DNA and SUV max to predict outcome with the best trade-off between sensitivity and specificity. The distribution of the subgroups of locoregional recurrence and distant recurrence were skewed; hence, a Wilcoxon rank sum test of two independent samples was used to compare the value of EBV DNA and SUV max between the two subgroups. Overall survival (OS) was calculated from the date of recurrence diagnosis to the date of death from any cause or patient censoring at the date of the last follow-up. Median OS values were estimated using the Kaplan-Meier method, and groups of interest were compared using log-rank tests. 
Results

Baseline characteristics and survival time in the subgroups of patients with locoregional or distant recurrence
A profile of this study is shown in Fig 1. Between July 2007 and December 2013, 208 patients were assessed and entered into this study. Fourteen cases were excluded: five due to diabetes or plasma glucose>200 mg/dl, two because there was not an initial failure after definitive radiotherapy, and the others due to attrition during follow-up or incomplete medical records. Therefore, 194 patients in all were eligible for analysis, among which 160 were men and 34 were women. Patient characteristics are described in Table 1 . The primary histologic type of the 194 cases, 178 cases presented non-keratinizing undifferentiated carcinoma (formerly WHO type III), 4 cases presented non-keratinizing differentiated carcinoma (formerly WHO type II), only 1 presented keratinizing squamous cell carcinoma (type I) and 11 patients missed data. The mean age of all patients was 43.9 years (range, 10 to 70 years). Among the 194 patients, 107 had locoregional recurrence only, and 87 had distant failure with or without locoregional recurrence. 103 cases were diagnosed recurrence by pathology and 91 cases were diagnosed by imaging test. Based on whether the patients exhibited distant failure, all patients were divided into two subgroups, the locoregional recurrence group and the distant recurrence group. At the time of the final follow-up, 30 of 107 patients (28%) had died in the locoregional recurrence subgroup, whereas 31 of 87 patients (35.6%) had died in the distant recurrence subgroup. The median concentration of plasma EBV DNA was 4,000 copies/ml for patients with locoregional recurrence only, which was much lower than that of patients with distant metastasis (34,900 copies/ml, P<0.001). The median SUV max for patients with distant recurrence was much higher than that of the locoregional recurrent patients (13.3 vs. 11.50, P<0.001). We found that EBV DNA could not be detected in 37 of 107 patients (34.6%) with locoregional recurrence only and 12 of 87 patients (13.8%) with distant recurrence. Spearman correlation analysis demonstrated that EBV DNA levels positively correlated with number of metastases and that SUV max correlated with clinical restage and number of metastases (S1 Table) .
The mean follow-up time was 18.09 months (range, 0.62 to 55.88 months). Survival time was analyzed using the Kaplan-Meier method and compared with log-rank tests between the locoregional recurrence and distant recurrence subgroups. The results are shown in Fig 2. The median survival time for NPC patients with locoregional recurrence or distant recurrence was 42.45 months (95%CI, 26.11 to 58.79 months) and 23.20 months (95%CI, 18.49 to 27.90 months), respectively (P = 0.001, as shown in Fig 2) .
Prognostic value of EBV DNA and SUV max for patients with locoregional recurrence Next, we constructed ROC curves for death events to separately identify the impact of SUV max and EBV DNA levels on the survival of locoregional recurrent and metastatic NPC patients. We used a series of cutoff points and finally selected the best cutoff values as the threshold for the subsequent binary variable analysis (Tables 2 and 3 ). With the value of 8.65 as the optimal cutoff point for patients with locoregional recurrence, patients with SUV max 8.65 were found to have the most discriminate significance for OS (P = 0.005; Fig 3) . The median OS was 31.05 months (95%CI, 22.76 to 39.33 months) for the patients with SUV max 8.65, which was much shorter than that of the patients with SUV max < 8.65, who had a value of 55.88 months (95%CI, 39.77 to 58.70 months). Selecting the optimal cutoff point of 4000 copies/ml for EBV DNA, the Kaplan-Meier method demonstrated that there was no significant difference for OS between the low and high EBV DNA groups (P = 0.541; Fig 3) . Univariate analysis showed that a locoregional SUV max 8.65 was an unfavorable prognostic factor (P = 0.013; Table 2 ). To adjust for SUV max , the potentially associated parameters were introduced into the multivariable Cox regression model. The multivariate results confirmed that an SUV max 8.65 was a highly significant predictor for OS for locoregional recurrent patients (HR = 4.882; 95%CI = 1.055-22.590; P = 0.042; Table 2 ), independent of restage, EBV DNA level, family history of tumor, gender and age. These results indicated that the predictive ability of SUV max was superior to that of EBV DNA for predicting survival for patients with locoregional recurrence.
Prognostic value of EBV DNA levels and SUV max for patients with distant recurrence
We found that ROC curves, which identified the impact of SUV max and EBV DNA levels on the survival of metastatic NPC patients, had significantly different areas under the curve (AUCs). As S1 Fig shows, the AUC of EBV DNA was 0.664 (95%CI, 0.543 to 0.784), which is larger than that of SUV max , which had an AUC of 0.595 (95%CI, 0.455 to 0.735). The best cutoff was selected for metastatic NPC, and patients were categorized into two groups for separate Kaplan-Meier analysis according to their cutoff values of EBV DNA and SUV max . Fig 4 shows the Kaplan-Meier estimates for OS based on EBV DNA and SUV max . SUV max 13.55 and EBV DNA21,100 copies/ml were two factors that significantly associated with shorter OS (P = 0.006 and P = 0.015, respectively; Fig 4) . For the patients with SUV max 13.55, the median OS was much shorter compared with the patients with SUV max <13.55, with values of 17.12 months (95%CI, 12.95-21.29 months) vs. 36.50 months (95%CI, 9.21-63.79 months), respectively (P = 0.006). Similarly, patients with EBV DNA21,100 copies/ml had a shorter median OS of 21.72 months (95%CI, 14.15-29.29 months) compared with 31.65 months (95%CI, 25.41-37.89 months, P = 0.015) in the group with EBV DNA<21,100 copies/ml. Univariate Cox proportional hazards regression analyses revealed that being male and having an age46, EBV DNA21,100 copies/ml, number of metastases3 and an SUV max 13.55 was strongly associated with an unfavorable OS (Table 3) . Multivariate Cox proportional hazards regression analyses further confirmed that age (HR = 2.687; 95%CI = 1.156-6.244; P = 0.022) and EBV DNA (HR = 3.269; 95%CI = 1.383-7.728; P = 0.007) were highly significant prognostic factors for OS, and SUV max of patients with distant recurrence was borderline significant (HR = 2.415; 95%CI = 0.956-6.101; P = 0.062). These results showed that the predictive ability of EBV DNA was superior to that of SUV max for predicting survival for patients with distant metastasis. Prognostic value of SUV max in patients with undetectable EBV DNA A total of 49 patients (37 of 107 with locoregional recurrences and 12 of 87 with distant recurrences) had undetectable EBV DNA levels. To assess the prognostic value of SUV max in patients with undetectable EBV DNA levels, this special population was further analyzed using the Kaplan-Meier method and compared with log-rank tests. Because the analysis was limited by a small number of samples, patients with locoregional or distant recurrence with undetectable EBV DNA levels were analyzed together. A cutoff SUV max of 8.65 was used for the analysis. The results are presented in S2 Fig. A higher SUV max (SUVmax8.65) was strongly correlated with poor OS in recurrent patients with undetectable EBV DNA (P = 0.011). Multivariate analysis demonstrated that a level of SUV max 8.65 was still a significant predictor for OS for recurrent patients with undetectable EBV DNA (HR = 5.093; 95%CI = 1.093-23.721; P = 0.038; S2 Table) . These results illustrated that SUV max is still an effective prognostic indicator for those with undetectable levels of EBV DNA.
Discussion
Prognostic factors, which can be assayed noninvasively, are extraordinarily vital for cancer treatment stratification and potentially improving treatment outcome. The recent demonstration of the use of 18 F-FDG-PET SUV max and EBV DNA levels in NPC patients has opened up new possibilities for detecting and monitoring recurrent NPC patients in southern China and Southeast Asia. [9, 21] A study by Chang suggested that tumor TLG, nodal TLG, total TLG, tumor SUV max , and nodal SUV max were all significantly associated with plasma EBV DNA load. [27] However, this correlation of SUV max and EBV DNA was not found in this study of patients with recurrent NPC. We explored and compared the prognostic implication of SUVmax and EBV DNA in subgroups of locoregional recurrent or distant recurrent NPC patients in the present study. Intriguingly, we found that the value of SUV max was an effective prognostic biomarker for overall survival in patients with locoregional recurrence and patients with undetectable EBV DNA levels. According to our findings, the predictive power of EBV DNA load was superior to that of SUV max , although both distant SUV max and EBV DNA load were independent prognostic factors that predicted survival for patients with distant recurrence. Studies are lacking on prognostic markers for patients with locoregional recurrence. Chan explored the value of SUV max and EBV DNA in predicting the outcome of nasopharyngectomy and cervical lymphadenectomy for patients with locoregional recurrent NPC. [17] However, the study was limited as it was unable to predict prognosis, although it found that preoperative EBV DNA and SUV max levels of tumors had a predictive value for surgical resection margin status. In this study of a subgroup of 107 locoregional recurrent NPC patients, we noted that a higher SUV max , rather than EBV DNA level, had significant clinical value for predicting poor OS. To our knowledge, previous studies indicated that EBV DNA was associated with the TNM stage and reflected the tumor burden. Although there are controversial opinions regarding from where the plasma/serum circulating EBV DNA is derived, an increasing number of studies indicate that EBV DNA originates from tumor lesions and correlates with tumor load. . SUV max , the maximal standardized uptake value.
doi:10.1371/journal.pone.0122756.t003 [28] [29] [30] In contrast to other head and neck cancer and epithelial malignancy in general, a unique feature of NPC is its strong association with EBV. The life cycle of EBV includes latent and lytic stages. In NPC tumor cells, EBV hides in a latent status and latent viral genomes are periodically reactivated to the lytic cycle. [31, 32] For the patients with advanced stage disease, more NPC cells were reactivated into lytic stage, and released quantities of EBV DNA fragment into the circulation by lysis death. [33] Patients with locoregional recurrence showed a relatively low tumor load and therefore displayed low EBV DNA levels, partially explaining why EBV DNA was not an effective prognostic indicator for locoregional recurrence. In contrast, SUVmax of a lesion tends to show its metabolic activity and thus the aggressiveness of the tumor. [34, 35] In addition, a systematic review of 1813 patients from the published literature showed that 18 F-FDG PET/CT imaging was significantly superior to MRI and CT for the diagnosis of recurrent locoregional disease, [36] and according to our findings, the SUV max of 18 F-FDG PET/CT also serves as a valuable predictive factor. Furthermore, the overexpression of glucose transporter 1 (GLUT1) has been shown to be closely related to 18 F-FDG uptake in human cancer, [37] and it has been widely reported that GLUT1 correlates with poor prognosis and tumor aggressiveness in lung [38] and colorectal [39] carcinomas and in squamous cell carcinoma of the head and neck [40] . Together, these results suggest a possible explanation for why the predictive ability of SUV max was superior to that of EBV DNA levels in patients with locoregional recurrence. However, there were still some NPC cases accompanied concurrently by locoregional recurrence and subclinical distant metastasis. In this circumstance, the plasma EBV DNA test should be routinely performed to monitor disease progression during the retreatment and follow up. Several studies have also been published concerning the predictive value of SUV max and EBV DNA load for distant recurrence after treatment. These studies demonstrated that EBV DNA levels in metastatic/recurrent NPC could predict tumor response and patient survival. [15, 18] , However, the two studies failed to reveal the definite pattern of recurrence (i.e., locoregional recurrence or distant recurrence). Chan revealed that SUV max was an effective biomarker for predicting prognosis in metastatic NPC. [41] Consistent with these results, we found that patients with higher distant SUV max values presented a worse overall survival compared with patients with lower distant SUV max values. It has been reported that EBV DNA load is a better prognosticator for distant metastatic recurrence than locoregional recurrence in NPC. [42] Consistent with this previous report, we found that EBV DNA load is an independent prognostic factor for overall survival in patients with distant recurrence but not in patients with locoregional recurrence. It is also logical to suggest that the higher tumor burden in patients with distant recurrence accounts for the better predictive ability of the level of EBV DNA. Another alternative explanation for the better predictive ability of EBV DNA load in patients with distant recurrence compared with patients with locoregional recurrence is that distant recurrences originate from subclinical micro-metastases in the circulation that are seeded from the primary tumor before the commencement of radiation therapy. [42] We also found that the predictive ability of SUV max is inferior to that of the level of EBV DNA for patients with distant recurrence. It is worth noting that SUV max is only the reflection of metabolism activity of a locoregional site and cannot sufficiently reflect tumor cells in the circulation, which are known as micro-metastases. Thus, it is reasonable to hypothesize that for those with distant metastasis, there may be numerous micro-metastases in the circulation. Present imaging modalities are not sufficient to discover this micro-metastasis. However, the higher EBV DNA concentration in patients with distant recurrent NPC, as reflected in our results, might closely correlate with the degree of micro-metastasis. In our analysis of 194 recurrent patients, 49 presented with undetectable EBV DNA levels, and further study showed that SUV max was also predictive of survival for these patients. NPC patients with undetectable EBV DNA levels have been reported in previous studies. Yip et al. summarized previous studies and found that an EBV DNA qPCR achieved sensitivities of tumor detection of 22-86%, 48-95%, 74-100% and 79-100% in stage I, II, III and IV patients, respectively. [43] They further reviewed 6 studies from 2003 to 2013 that compared the ability of post-treatment EBV DNA loads to detect distant metastasis (DM) and local recurrence (LR) or locoregional recurrence (LRR). The detection rate for DM ranged from 55% to 96% and varied from 0% to 67% for LR/LRR. It is noteworthy that a low or undetectable EBV DNA load does not necessarily predict good prognosis. Nevertheless, SUV max is an independent determinant to EBV DNA load in predicting survival for patients with recurrent NPC and undetectable EBV DNA.
However, some limitations remain in the present study. First, our study was limited by the relatively small sample size and short follow-up time. Second, the measurements were recorded from a single center. Third, the clinical application of quantitative plasma EBV DNA results has been limited by varying sensitivities when different segments of viral gene or different viral genes are assayed in different study group [44] [45] [46] . Hence, a larger, multicenter cohort study with unified standardized procedures is warranted.
In conclusion, we clearly demonstrated that pretreatment locoregional SUV max level was the only independent predictive factor of OS for patients with locoregional recurrence, but for patients with distant recurrence, the predictive ability of EBV DNA load was superior to that of SUV max . In addition, SUVmax remains an effective indicator for patients with undetectable amounts of EBV DNA. This study may guide individualized treatment for recurrent NPC patients. Further prospective, multicenter investigations to evaluate the feasibility and role of SUV max and EBV DNA concentration for prognostication in recurrent NPC are warranted.
Supporting Information 
